{"data":[{"PressReleaseId":"1656","PressReleaseDate":"August 28, 2024","Headline":"Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences","ShortBody":"Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person in New York City: Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Thursday, September 5, 2024, at 1:50pm ET Baird 2024 Global Healthcare Conference: Fireside chat on Tuesday, September 10, 2024, at 3:45pm ET H.C. Wainwright 26th Annual Global Investment Conference: Corporate presentation on Wednesday, September 11, 2024, at 8:30am ET A live webcast of each conference event can be accessed under \u201cEvents and Presentations\u201d in the Investor section of the Company\u2019s website, https:\/\/investors.amylyx.com\/news-events\/events , and will be available for replay for 90 days following the events. About Amylyx Pharmaceuticals Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with","PressReleaseUrl":"https:\/\/www.amylyx.com\/news\/amylyx-pharmaceuticals-to-participate-in-upcoming-investor-conferences-1"},{"PressReleaseId":"1646","PressReleaseDate":"August 12, 2024","Headline":"Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer\u2019s Disease Pathology and Neurodegeneration","ShortBody":"- Findings from exploratory analysis of the PEGASUS trial provide preliminary evidence that AMX0035 engages multiple pathological pathways related to neurodegeneration, including tau Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) today announced the publication of exploratory analyses on cerebrospinal fluid (CSF) biomarkers from participants with Alzheimer\u2019s disease (AD) from the Phase 2 PEGASUS trial. Data analyses suggest that treatment with AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) resulted in consistent changes in AD and neurodegeneration CSF biomarkers in participants with a broad range of disease severity. The results were published in the peer-reviewed medical journal Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions , a journal of the Alzheimer\u2019s Association. \u201cAlzheimer\u2019s disease is defined by amyloid plaques and tau tangles, but it\u2019s now understood that these pathologies are accompanied by alterations","PressReleaseUrl":"https:\/\/www.amylyx.com\/news\/amylyx-pharmaceuticals-announces-publication-of-data-showing-the-encouraging-effects-of-amx0035-on-cerebrospinal-fluid-biomarkers-of-core-alzheimers-disease-pathology-and-neurodegeneration"},{"PressReleaseId":"1641","PressReleaseDate":"August 08, 2024","Headline":"Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results","ShortBody":"Expanded pipeline with avexitide, a Phase 3-ready GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations; Phase 3 program initiation in post-bariatric hypoglycemia (PBH) on track for Q1 2025 Company expects to present updated data from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome at ISPAD 2024, including data from all 12 participants at Week 24 and any participant who completed their Week 36 or 48 assessment prior to the data cutoff Multiple ascending dose clinical trial of AMX0114 in people living with ALS planned to initiate in the second half of 2024 Cash, cash equivalents and short-term investments of $309.8 million at June 30, 2024; cash runway expected into 2026 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) today reported financial results for the second quarter ended June 30, 2024. \u201cWe recently expanded our late-stage pipeline with","PressReleaseUrl":"https:\/\/www.amylyx.com\/news\/amylyx-pharmaceuticals-reports-second-quarter-2024-financial-results"},{"PressReleaseId":"1636","PressReleaseDate":"August 05, 2024","Headline":"Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024","ShortBody":"Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) will report its second quarter 2024 financial results on Thursday, August 8, 2024. Amylyx\u2019 senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (800)-836-8184 (U.S. & Canada) or +1 (646)-357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under \u201cEvents and Presentations\u201d in the Investor section of the Company\u2019s website, https:\/\/investors.amylyx.com\/news-events\/events . The webcast will be archived and available for replay for 90 days following the event. About Amylyx Pharmaceuticals Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal","PressReleaseUrl":"https:\/\/www.amylyx.com\/news\/amylyx-pharmaceuticals-to-report-second-quarter-2024-financial-results-on-august-8-2024"}],"count":140}